Skip to main content

Table 2 Expected number of newly diagnosed U.S. patients by HLA-1 type and cancer entity

From: Identification and ranking of recurrent neo-epitopes in cancer

A)

             

Cancer entity

Study

Number of patients

HLA-A*01:01 (7.61%)

HLA-A*02:01 (20.36%)

HLA-A*03:01 (6.60%)

HLA-A*11:01 (4.37%)

HLA-B*07:02 (6.51%)

HLA-B*08:01 (4.80%)

HLA-B*15:01 (4.46%)

HLA-C*04:01 (16.69%)

HLA-C*06:02 (5.72%)

HLA-C*07:01 (9.28%)

HLA-C*07:02 (15.39%)

Bladder Urothelial Carcinoma

BLCA

69300

340

638

197

152

142

112

89

223

376

596

383

Invasive Breast Carcinoma

BRCA

204800

110

1090

461

199

108

375

120

482

1411

2305

1234

Cervical Squamous Cell Carcinoma

CESC

14000

58

135

16

17

13

14

23

142

27

66

152

Colon Adenocarcinoma

COAD

154840

861

1628

770

760

450

222

375

2961

1019

1620

1800

Esophageal Adenocarcinoma

ESCA

4750

23

151

26

16

20

5

13

101

23

26

83

Glioblastoma Multiforme

GBM

3204

7

17

3

7

0

0

3

8

5

3

3

Head & Neck Squamous Cell Carcinoma

HNSC

58000

43

208

112

45

81

11

81

301

136

220

175

Renal Clear Cell Carcinoma

KIRC

57600

13

70

23

0

0

8

0

0

10

0

26

Papilliary Renal Cell Carcinoma

KIRP

8064

0

6

0

3

0

0

0

29

0

0

0

Acute Myeloid Leukemia

LAML

13500

77

115

0

8

49

0

0

0

48

9

73

Hepatocellular Carcinoma

LIHC

29700

12

496

131

84

69

12

7

68

69

112

174

Lung Squamous Cell Carcinoma

LUSC

66000

181

642

328

168

282

13

77

593

151

172

366

Serous Ovarian Cancer

OV

16800

26

24

33

10

15

2

14

39

9

14

36

Prostate Adenocarcinoma

PRAD

260000

120

852

69

69

34

50

70

175

387

628

1202

Melanoma

SKCM

75000

2649

7890

1817

936

861

530

203

2186

438

1000

2457

Stomach Adenocarcinoma

STAD

25000

47

172

56

66

26

8

30

206

114

166

130

Thyroid Cancer

THCA

46400

394

0

0

0

0

14

0

0

0

0

44

Endometrial Carcinoma

UCEC

55000

942

2804

817

501

369

290

493

2222

856

1602

1779

Total

 

1161958

5904

16936

4858

3033

2517

1666

1598

9736

5080

8539

10116

B)

             

Number of candidates in diseases

  

55

91

68

64

33

24

24

48

48

50

55

  1. A) Expected number of patients of a given HLA-1 type who harbor at least one potentially immunogenic neo-epitope candidate for that HLA-1 type. Both the cancer incidence and the allele frequency are estimated for the U.S. population. The probability that a patient carries at least one variant from the set of neo-epitope candidates is computed under the assumption that the occurrence of variants in a cancer patient stems from statistically independent events. B) Number of neo-epitope candidates identified in the 18 studies shown in A, which are predicted to be strong binders to the corresponding HLA-1 type